Severe ulceration over mandibular torus in an ovarian cancer patient receiving bevacizumab therapy.
Publication
, Journal Article
Teoh, D; Won, JS; Eisberg, R; Nolte, K; Secord, AA
Published in: Gynecol Oncol Case Rep
2011
► Bevacizumab may increase the risk of mucosal ulceration and subsequent bone necrosis. ► Patients receiving bevacizumab should be closely monitored for dental symptoms.
Duke Scholars
Published In
Gynecol Oncol Case Rep
DOI
ISSN
2211-338X
Publication Date
2011
Volume
1
Issue
1
Start / End Page
20 / 21
Location
Netherlands
Citation
APA
Chicago
ICMJE
MLA
NLM
Teoh, D., Won, J. S., Eisberg, R., Nolte, K., & Secord, A. A. (2011). Severe ulceration over mandibular torus in an ovarian cancer patient receiving bevacizumab therapy. Gynecol Oncol Case Rep, 1(1), 20–21. https://doi.org/10.1016/j.gynor.2011.09.001
Teoh, Deanna, John S. Won, Robert Eisberg, Kimberly Nolte, and Angeles Alvarez Secord. “Severe ulceration over mandibular torus in an ovarian cancer patient receiving bevacizumab therapy.” Gynecol Oncol Case Rep 1, no. 1 (2011): 20–21. https://doi.org/10.1016/j.gynor.2011.09.001.
Teoh D, Won JS, Eisberg R, Nolte K, Secord AA. Severe ulceration over mandibular torus in an ovarian cancer patient receiving bevacizumab therapy. Gynecol Oncol Case Rep. 2011;1(1):20–1.
Teoh, Deanna, et al. “Severe ulceration over mandibular torus in an ovarian cancer patient receiving bevacizumab therapy.” Gynecol Oncol Case Rep, vol. 1, no. 1, 2011, pp. 20–21. Pubmed, doi:10.1016/j.gynor.2011.09.001.
Teoh D, Won JS, Eisberg R, Nolte K, Secord AA. Severe ulceration over mandibular torus in an ovarian cancer patient receiving bevacizumab therapy. Gynecol Oncol Case Rep. 2011;1(1):20–21.
Published In
Gynecol Oncol Case Rep
DOI
ISSN
2211-338X
Publication Date
2011
Volume
1
Issue
1
Start / End Page
20 / 21
Location
Netherlands